Dana L Casey1, Brian H Kushner2, Nai-Kong V Cheung2, Shakeel Modak2, Ellen M Basu2, Stephen S Roberts2, Michael P LaQuaglia3, Suzanne L Wolden4. 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: For patients with high-risk neuroblastoma (HR-NB), a dose of 21 Gy to the primary tumor site after gross total resection (GTR) provides excellent local control. However, no clinical trial has specifically evaluated the optimal dose of radiation therapy (RT), and RT-related long-term toxicities are of increasing concern. We sought to assess local control, survival outcomes, and toxicity after a reduction in dose to the primary site from 21 Gy to 18 Gy. METHODS AND MATERIALS: After induction chemotherapy and GTR, patients with HR-NB were enrolled and treated on an RT dose-reduction prospective trial with 18 Gy hyperfractionated RT given in twice-daily fractions of 1.5 Gy each. RESULTS: The 25 study subjects were 1.6 to 9.5 (median, 4.3) years old at enrollment and included 23 (92%) with stage IV and II (8%) with MYCN-amplified stage III disease. Eleven (44%) were in complete remission (CR), and 14 (56%) had persistence of osteomedullary disease postinduction. Three patients (12%) received proton therapy, and the rest received intensity modulated photon therapy. After a follow-up of 1.8 to 4.2 (median, 3.5) years from initiation of RT, no failures occurred within the RT field; 3 patients had marginal recurrences. The respective 3-year progression-free and overall survival rates were 54.5% and 90.9% for patients in first CR and 42.9% and 76.2% for patients not in metastatic CR. Acute toxicity was negligible. CONCLUSIONS: Reduced-dose RT with 18 Gy did not compromise local control or survival outcomes in our cohort of patients with HR-NB after GTR. These findings support assessing further RT dose reduction and validation on a larger, multi-institutional trial.
PURPOSE: For patients with high-risk neuroblastoma (HR-NB), a dose of 21 Gy to the primary tumor site after gross total resection (GTR) provides excellent local control. However, no clinical trial has specifically evaluated the optimal dose of radiation therapy (RT), and RT-related long-term toxicities are of increasing concern. We sought to assess local control, survival outcomes, and toxicity after a reduction in dose to the primary site from 21 Gy to 18 Gy. METHODS AND MATERIALS: After induction chemotherapy and GTR, patients with HR-NB were enrolled and treated on an RT dose-reduction prospective trial with 18 Gy hyperfractionated RT given in twice-daily fractions of 1.5 Gy each. RESULTS: The 25 study subjects were 1.6 to 9.5 (median, 4.3) years old at enrollment and included 23 (92%) with stage IV and II (8%) with MYCN-amplified stage III disease. Eleven (44%) were in complete remission (CR), and 14 (56%) had persistence of osteomedullary disease postinduction. Three patients (12%) received proton therapy, and the rest received intensity modulated photon therapy. After a follow-up of 1.8 to 4.2 (median, 3.5) years from initiation of RT, no failures occurred within the RT field; 3 patients had marginal recurrences. The respective 3-year progression-free and overall survival rates were 54.5% and 90.9% for patients in first CR and 42.9% and 76.2% for patients not in metastatic CR. Acute toxicity was negligible. CONCLUSIONS: Reduced-dose RT with 18 Gy did not compromise local control or survival outcomes in our cohort of patients with HR-NB after GTR. These findings support assessing further RT dose reduction and validation on a larger, multi-institutional trial.
Authors: Caroline Laverdière; Nai-Kong V Cheung; Brian H Kushner; Kim Kramer; Shakeel Modak; Michael P LaQuaglia; Suzanne Wolden; Kirsten K Ness; James G Gurney; Charles A Sklar Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2018-02-22 Impact factor: 3.167
Authors: R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: R J Packer; J Goldwein; H S Nicholson; L G Vezina; J C Allen; M D Ris; K Muraszko; L B Rorke; W M Wara; B H Cohen; J M Boyett Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Heather G Gatcombe; R B Marcus; Howard M Katzenstein; Mourad Tighiouart; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-11 Impact factor: 7.038
Authors: Daphne A Haas-Kogan; Patrick S Swift; Michael Selch; Gerald M Haase; Robert C Seeger; Robert B Gerbing; Daniel O Stram; Katherine K Matthay Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Brian H Kushner; Irina Ostrovnaya; Irene Y Cheung; Deborah Kuk; Shakeel Modak; Kim Kramer; Stephen S Roberts; Ellen M Basu; Karima Yataghene; Nai-Kong V Cheung Journal: Oncotarget Date: 2016-01-26
Authors: Danny Jazmati; Sarina Butzer; Barbara Hero; Dalia Ahmad Khalil; Julien Merta; Christian Bäumer; Gina Plum; Jörg Fuchs; Friederike Koerber; Theresa Steinmeier; Sarah Peters; Jerome Doyen; Theresa Thole; Matthias Schmidt; Christoph Blase; Stephan Tippelt; Angelika Eggert; Rudolf Schwarz; Thorsten Simon; Beate Timmermann Journal: Front Oncol Date: 2021-01-20 Impact factor: 6.244